Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 16/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764372 | 0.84 | TSHR (0.45) | TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL12444340 | 0.84 | TSHR (0.45) | TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL765584 | 0.76 | AR (0.36) | PDE3BPDE3AP2RY12MAPK1TSHR | |
| SCHEMBL764351 | 0.73 | CNR1 (0.35) | — | |
| SCHEMBL10046478 | 0.69 | CNR2 (0.41) | — | |
| SCHEMBL10046498 | 0.68 | AR (0.38) | MAPK1TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL10046622 | 0.68 | HTT (0.44) | TSHRCYP1A2SMN1; SMN2 | |
| SCHEMBL3312696 | 0.64 | FAAH (0.50) | TSHRSMN1; SMN2 | |
| SCHEMBL3316341 | 0.64 | FAAH (0.50) | TSHRSMN1; SMN2 | |
| SCHEMBL18237399 | 0.64 | POLB (0.42) | TSHRCYP1A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325169-B1 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | Univ Virginia Patent Found (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987321-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481580-B2 | interleukin 1, 12, tumor necrosis factor alpha, and trigger interferon- gamma antagonist; antiinflammatory , antidiabetic agent, autoimmune disorders; active side chain moiety (5-R-hydroxyhexyl) of lisofyllin, greater potency and oral bioavailability than lisofylline | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2325169-A9 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | University Of Virginia Patent Foundation (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2325169-A2 | Lisofylline analogues and their pharmeacuetical uses | University Of Virginia Patent Foundation (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINA PATENT FOUNDATION | 2008-06-19 | — | — | US | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| WO-2007027719-A2 | LISOFYLLINE ANALOGUES AND THEIR PHARMEACUETICAL USES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | PDE3B 611/4885PDE3A 765/4885P2RY12 67/4885 |
| US-20140018355-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | PDE3B 740/4885PDE3A 309/4885P2RY12 2281/4885 |
| US-20080146544-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | LPXN, LCT, SI | PDE3B 740/4885PDE3A 309/4885P2RY12 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.